Mitoxantrone (12 mg/m2) v placebo in relapsing-remitting or secondary progressive multiple sclerosis at 24 months†
| Outcomes | Mitoxantrone | Placebo | Mann-Whitney difference (95% CI) | p Value‡ |
|---|---|---|---|---|
| †AIN = ambulation index; EDSS = Expanded Disability Status Scale; N/R = not reached in 24 months; SNS = standardised neurological status; composite outcome = EDSS, AIN, SNS, number of treated relapses, and time to first treated relapse. CI defined in glossary. | ||||
| ‡All significant differences favour mitoxantrone. | ||||
| Global difference in composite outcome | – | – | 0.30 (0.17 to 0.44) | <0.001 |
| Mean change from baseline in EDSS score | −0.13 | 0.23 | 0.24 (0.04 to 0.44) | <0.019 |
| Mean change from baseline in AIN score | −0.30 | 0.77 | 0.21 (0.02 to 0.40) | <0.031 |
| Mean change from baseline in SNS score | −1.07 | 0.77 | 0.23 (0.03 to 0.43) | <0.027 |
| Number of treated relapses | 24.08 | 76.77 | 0.39 (0.18 to 0.59) | <0.001 |
| Median time to first treated relapse (mo) | N/R | 14.19 | 0.44 (0.20 to 0.69) | <0.001 |